Abstract
Much attention is presently devoted to the treatment of lymphoma using monoclonal antibodies. Unfortunately, preparations such as Rituximab (MabThera) are not produced in the Russian Federation and must be imported from abroad. It was shown that H1-type histones with activities similar to that of Rituximab can be used for such therapy. We have developed an pilot-scale technology for the production of recombinant N,N-bis-met-histone H1.3. The activity and purity of the obtained preparation were demonstrated in several tests. The produced amount of active pharmaceutical ingredient was sufficient to start clinical trials in Russia.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
